Drug intelligence / Profile preview

melapuldencel-T + sargramostim

Development stage: Unknown
Lead developer: Lisata Therapeutics
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intradermal (typical For Dendritic Cell Vaccines Like melapuldencel-T, Though Some Protocols May Use Intravenous Or Subcutaneous Routes), Subcutaneous (sargramostim)

Overview

melapuldencel-T + sargramostim is an investigational combination immunotherapy for advanced melanoma. melapuldencel-T is an autologous dendritic cell-based vaccine derived from the patient’s own tumor, designed to stimulate a cancer-targeted immune response. Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that enhances the differentiation, activation, and function of immune cells, especially dendritic cells, neutrophils, and macrophages. In this combination, melapuldencel-T presents tumor antigens to the immune system, while sargramostim acts as an immune adjuvant to increase vaccine potency by promoting antigen-presenting cell function and linking innate and adaptive immunity. The combination is under investigation for use in metastatic or unresectable melanoma.

Brand names: Leukine (for sargramostim)
Other names: GM-CSF (for sargramostim)rhu GM-CSF (for sargramostim)

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on melapuldencel-T + sargramostim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on melapuldencel-T + sargramostim.

Explore the full profile